Your role in our mission Working as a SQL Analyst at Gainwell, you will be instrumental in the development of applications stacks including front-end, database, and API architecture. Apply modern 'Software Development' techniques to desig...
specifications to architect scalable and efficient integration solutions. · Implement best practices for API design, data mapping...(s) such as Dell Boomi Developer or Dell Boomi Architect · Basic understanding of Boomi administration. If you share our mindset...
and their potential application for service offerings and products. Work with architect and lead engineers for solutions to meet.... Work with architect and lead engineers for solutions to meet functional and non-functional requirements. Demonstrated...
Job Description Lead Data Architect - Data Solutions We are seeking a talented, motivated and self-driven... journey to become the premier “Data First” commercial biopharma organization. As a Lead Data Architect, you will be part...
Chile, home to the world’s biggest lithium reserves, is confident that investors will compete for licenses to drill new deposits even amid a worsening global glut that’s squeezing the battery-metal industry. Continue Reading »
Gold Prices Today: Gold of 99.9 and 99.5 per cent purity grew ₹2,320 each in the last seven trading sessions. However, silver prices declined ₹500 to ₹93,500 per kg from the previous close Continue Reading »
At 11:57 a.m. ET, the Dow Jones Industrial Average rose 0.58 per cent, the S&P 500 gained 0.14 per cent, the Nasdaq Composite lost 0.19 per cent Continue Reading »
Expert view: Mohit Khanna anticipates the Union Budget 2025 will prioritize youth, women, the poor, and farmers, with increased spending on rural housing, irrigation, and employment-linked incentives. Continue Reading »
HPCL Q3 Results: The state-owned OMC's revenue from operations in the third quarter of current fiscal rose to ₹1.10 lakh crore led by better marketing margins. Continue Reading »
Dr Reddy's Laboratories reported a 2% YoY increase in PAT to ₹1,413.3 crore for Q3 2024, driven by a 16% rise in revenue to ₹8,358.6 crore. The company invested ₹6.7 billion in R&D, focusing on complex generics and biosimilars. Continue Reading »